Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Merck
Colorcon
Baxter
Moodys

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

XOFLUZA Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Xofluza patents expire, and when can generic versions of Xofluza launch?

Xofluza is a drug marketed by Genentech Inc and is included in one NDA. There are three patents protecting this drug.

This drug has sixty-four patent family members in twenty-two countries.

The generic ingredient in XOFLUZA is baloxavir marboxil. Two suppliers are listed for this compound. Additional details are available on the baloxavir marboxil profile page.

Summary for XOFLUZA
International Patents:64
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Clinical Trials: 2
Drug Prices: Drug price information for XOFLUZA
DailyMed Link:XOFLUZA at DailyMed
Drug patent expirations by year for XOFLUZA
Drug Prices for XOFLUZA

See drug prices for XOFLUZA

Generic Entry Opportunity Date for XOFLUZA
Generic Entry Date for XOFLUZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for XOFLUZA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
ShionogiN/A
Hoffmann-La RocheN/A
Hoffmann-La RochePhase 3

See all XOFLUZA clinical trials

US Patents and Regulatory Information for XOFLUZA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genentech Inc XOFLUZA baloxavir marboxil TABLET;ORAL 210854-001 Oct 24, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Genentech Inc XOFLUZA baloxavir marboxil TABLET;ORAL 210854-002 Oct 24, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Genentech Inc XOFLUZA baloxavir marboxil TABLET;ORAL 210854-001 Oct 24, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Medtronic
Dow
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.